Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Equity Ratio (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Equity Ratio for 7 consecutive years, with 0.86 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 5.35% year-over-year to 0.86, compared with a TTM value of 0.86 through Dec 2025, down 5.35%, and an annual FY2025 reading of 0.86, down 5.35% over the prior year.
  • Equity Ratio was 0.86 for Q4 2025 at Avidity Biosciences, down from 0.87 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.93 in Q3 2021 and bottomed at 0.8 in Q4 2023.
  • Average Equity Ratio over 5 years is 0.89, with a median of 0.9 recorded in 2022.
  • The sharpest move saw Equity Ratio dropped 11.96% in 2023, then grew 14.37% in 2024.
  • Year by year, Equity Ratio stood at 0.89 in 2021, then rose by 1.44% to 0.9 in 2022, then dropped by 11.96% to 0.8 in 2023, then rose by 14.37% to 0.91 in 2024, then dropped by 5.35% to 0.86 in 2025.
  • Business Quant data shows Equity Ratio for RNA at 0.86 in Q4 2025, 0.87 in Q2 2025, and 0.91 in Q1 2025.